Tuberc Respir Dis > Volume 62(5); 2007 > Article
Tuberculosis and Respiratory Diseases 2007;62(5):432-436.
DOI:    Published online May 1, 2007.
Dramatic Tumor Response to 2nd-line Pemetrexed/Cisplatin Combination Chemotherapy in Patient with Malignant Pleural Mesothelioma..
Seung Min Lee, Soon Young Ko, Tae Ho Seo, Jung Hyun Lee, Seung Oh Choi, Jeong Geun Lee, Wan Seop Kim, Tae Hoon Lee, Gwang Ha Yoo, Kye Young Lee
1Department of Internal Medicine, College of Medicine, Konkuk University, Seoul, Korea.
2Department of Radiology, College of Medicine, Konkuk University, Seoul, Korea.
3Department of Pathology, College of Medicine, Konkuk University, Seoul, Korea.
Malignant pleural mesothelioma (MPM) is a rare tumor that is difficult to clearly distinguish from an adenocarcinoma but usually has a poor prognosis. Numerous cytotoxic agents have been used in the primary treatment of MPM with limited success. A complete response is unusual and a partial response occurs in less than one-third of patients. Recently, a phase III trial showed that a combination of pemetrexed with cisplatin resulted in a significantly higher response rate and median survival time than with cisplatin alone. We encountered a case of a dramatic tumor response to pemetrexed/cisplatin combination chemotherapy in patients with MPM, which was resistant to the 1st-line gemcitabine/cisplatin therapy. After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had decreased dramatically with complete symptom relief. There was no chemotherapy-related toxicity or scheduled violation. The patient is under maintenance chemotherapy with the same regimen.
Key Words: Malignant pleural mesothelioma, Pemetrexed, Cisplatin

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2021 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next